Search clinical trials for: Sintilimab

Total 419 results

RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Sun Yat-sen University

Active, not recruiting

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Advanced Microsatellite Stable Colorectal Cancer | Metastatic Microsatellite-stable Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

SCLC

China
Tianjin Medical University Cancer Institute and...

Active, not recruiting

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Gastric Cancer Stage IV

China
Henan Cancer Hospital

Completed

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Extensive Disease Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Advanced Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; First People's Hospital of Foshan; National Cancer...

Active, not recruiting

EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) (EP-STAR)

Nasopharyngeal Carcinoma

China
Hua Li

Withdrawn

Radiofrequency Ablation in Combination With Lenvatinib and Sintilimab

Hepatocellular Carcinoma

China
Fudan University

Completed

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University
Innovent Biologics, Inc.

Active, not recruiting

HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (HAICPD1-HCC)

Hepatocellular Carcinoma

China
Beijing Friendship Hospital

Completed

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Advanced Solid Tumor

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)

Nasopharyngeal Neoplasms

China
Second Affiliated Hospital, School of Medicine,...

Completed

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

High-Risk Resectable NSCLC

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable | RAS Mutation

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Gastric Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Gastric Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Squamous NSCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Advanced or Metastatic NSCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Lung Neoplasms

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
XIANG YANQUN

Active, not recruiting

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Chemotherapy Effect | Metastatic Nasopharyngeal Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.; CSPC Pharmaceutical Group Limited

Completed

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Esophageal Squamous Cell Carcinoma

China
Fudan University

Active, not recruiting

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Biliary Tract Carcinoma | Initially Unresectable

China
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaborators

Active, not recruiting

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Hepatocellular Carcinoma Non-resectable

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

IBI188 Combination Therapy in Solid Tumors

Osteosarcoma | Lung Adenocarcinoma | Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Colorectal Cancer

China
Galderma R&D

Completed

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Henan Cancer Hospital

Active, not recruiting

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Galderma R&D

Completed

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
The First Affiliated Hospital with Nanjing Medical...
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） (neoSCORE)

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Completed

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Radiotherapy | Sintilimab | Anlotinib | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Early Stage | Peg-aspargase | Phase Two | Open

China
Zhejiang University

Active, not recruiting

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Hepatocellular Carcinoma

China
Qilu Hospital of Shandong University

Withdrawn

Neoadjuvant Immunotherapy to ESCC

Esophagus SCC

China
Huiqiang Huang

Completed

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Safety and Efficacy

China
Hunan Province Tumor Hospital

Completed

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (SUCCESS)

Non-small Cell Lung Cancer

China
Yongchang Zhang

Completed

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Zhejiang University

Terminated

Perioperative Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma

China

3

Subscribe